Nectar Lifesciences — 360° view

Nectar Lifesciences, a company in the Pharmaceuticals industry, reported revenue of ₹0.01 crore and net profit of ₹2.72 crore for the September 2026 quarter.

Nectar Lifesciences (NSE: NECLIFE) closed at ₹9.81 on 20 Nov 2026. Its market capitalisation is ₹191 crore.

Share price
₹9.81 (20 Nov 2026)
Market cap
₹191 Cr (20 Nov 2026)
Revenue
₹0 Cr (September 2026 quarter)
Net profit
₹3 Cr (September 2026 quarter)
ROCE
0.05% (FY26)
ROE
-31.3% (FY26)
Book value
₹29.3 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹13.50 / ₹9.55 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: NECLIFE

Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.